A novel community-based buprenorphine program client description and initial outcomes

Journal of Addiction Medicine

Volumn 8, Issue 1, 2014, Pages 40-46

  Daniels, Amy M ^a   Salisbury Afshar, Elizabeth ^b   Hoffberg, Adam ^c   Agus, Deborah ^b,c   Fingerhood, Michael I ^d  

^a Autism Speaks Inc   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Behavioral Health Leadership Institute   (United States)

^d JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Buprenorphine; Community; Opiate; Recovery; Transition

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE;

ADULT; ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH CARE NEED; HEALTH INSURANCE; HEALTH STATUS; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBSTANCE USE; TOXICOLOGY; TREATMENT OUTCOME;

ADULT; BALTIMORE; BUPRENORPHINE; COMMUNITY HEALTH SERVICES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84898768223     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000004     Document Type: Article

References (20)

1. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis 2008;46(12):1852-1858. doi: 10.1086/588297
2. Baltimore Substance Abuse Systems, Inc. Unpublished manuscript. The Baltimore Buprenorphine Initiative, Second Interim Progress Report. Available at: Http://www.baltimorehealth.org/info/2008-06.BBI2ndReport.pdf. Accessed November 18, 2013.
3. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001a;96(5):683-690. doi:10.1080/09652140020039053
4. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001b;96(9):1267-1278. doi:10.1080/09652140120070328
5. Becker WC, Fiellin DA, Merrill JO, et al. Opiate use disorder in the United States: Insurance status and treatment access. Drug Alcohol Depend 2008;94(1-3), 207-213. doi:10.1016/j.drugalcdep.2007.11.018
6. Boodram B, Golub ET, Ouellet LJ. Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago. Drug Alcohol Depend 2010;111(1/2):136-145. doi:10.1016/j.drugalcdep.2010.04.003
7. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opiate dependence: A systematic review and economic evaluation. Health Technol Assess 2007;11(9):1-171, iii-iv.
8. Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med 2008;40(7):500-506.
9. Gryczynski J, Schwartz RP, Salkever DS, et al. Patterns in admission delays to outpatientmethadone treatment in the United States. J Subst Abuse Treat 2011;41(4):431-439. doi:10.1016/j.jsat.2011.06.005
10. Huang B, Dawson DA, Stinson FS, et al. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2006;67(7):1062-1073.
11. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet 2008;372(9651):1733-1745. doi:10.1016/S0140-6736(08)61311-2.
12. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;3:1-57.
13. Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 2010;39(4):340-352. doi:10.1016/j.jsat.2010.07.009
14. Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009;37(4):426-430. doi: 10.1016/j.jsat.2009.05.003
15. Stein BD, Gordon AJ, Sorbero M, et al. The impact of buprenorphine on treatment of opiate dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine andmethadone. Drug Alcohol Depend 2012;123(1-3):72-78. doi:10.1016/j.drugalcdep.2011.10.016
16. Substance Abuse and Mental Health Services Administration. Results From the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012a.
17. Substance Abuse and Mental Health Services Administration. Drug Addiction Treatment Act of 2000. 2012b. Available at: Http://buprenorphine.samhsa. gov/data.html. Accessed August 11, 2012.
18. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH Report: Illicit Drug Use by Race/Ethnicity in Metropolitan and Non-Metropolitan Counties: 2004 and 2005. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2007.
19. The Kaiser Commission on Medicaid and the Uninsured. Medicaid: A Primer. (No. 7334-03). Menlo Park, CA: 2009.
20. Williams CT, Latkin CA. Neighborhood socioeconomic status, personal network attributes, and use of heroin and cocaine. AmJ Prev Med 2007;32(6) (suppl):S203-S210.